Related Experiment Video

Updated: Sep 13, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

Antisense strategies in the treatment of leukemias

B Calabretta1, T Skorski, M Z Ratajczak

  • 1Department of Microbiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Seminars in Oncology
|February 1, 1996
PubMed

Insights

Oligodeoxynucleotides show promise in treating leukemia by inhibiting cancer cell growth. Clinical trials are underway, but further research is needed to understand their full potential and mechanisms.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Oligodeoxynucleotides are synthetic DNA sequences designed to target specific mRNA molecules.
  • Gene expression can be inhibited by forming RNA-DNA duplexes with target mRNAs.
  • Previous studies have shown potential in using oligodeoxynucleotides to target oncogene-encoded mRNAs.

Purpose of the Study:

  • To evaluate the efficacy of oligodeoxynucleotides in inhibiting cancer cell proliferation and inducing cell death.
  • To assess the antileukemia effects of chemically modified oligodeoxynucleotides in preclinical models.
  • To investigate the ongoing clinical trials of oligodeoxynucleotides for hematologic malignancies.

Main Methods:

  • Delivery of oligodeoxynucleotides targeting oncogene-encoded mRNAs to human cells in culture.
  • Systemic administration of chemically modified oligodeoxynucleotides in murine models of human hematologic malignancies.
  • Phase 1 clinical trials involving ex vivo and systemic administration of oligodeoxynucleotides.

Main Results:

  • Inhibition of cell proliferation and, in some cases, cell death observed in human cells in culture.
  • Measurable antileukemia effects reported in some studies using murine models.
  • Ongoing phase 1 clinical trials are evaluating the safety and efficacy of these compounds.

Conclusions:

  • Oligodeoxynucleotides demonstrate potential as novel therapeutic agents for leukemia.
  • Further research is required to fully understand their uptake, distribution, mechanism of action, and metabolism.
  • Potential nonspecific effects associated with oligodeoxynucleotides need to be considered.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...